{"id":"https://openalex.org/W4317829366","doi":"https://doi.org/10.1358/dot.2023.59.1.3509751","title":"Ciltacabtagene autoleucel for the treatment of multiple myeloma","display_name":"Ciltacabtagene autoleucel for the treatment of multiple myeloma","publication_year":2023,"publication_date":"2023-01-01","ids":{"openalex":"https://openalex.org/W4317829366","doi":"https://doi.org/10.1358/dot.2023.59.1.3509751","pmid":"https://pubmed.ncbi.nlm.nih.gov/36811414"},"language":"en","primary_location":{"id":"doi:10.1358/dot.2023.59.1.3509751","doi":"https://doi.org/10.1358/dot.2023.59.1.3509751","is_oa":false,"landing_page_url":"https://doi.org/10.1358/dot.2023.59.1.3509751","pdf_url":null,"source":{"id":"https://openalex.org/S202615048","display_name":"Drugs of today","issn_l":"0025-7656","issn":["0025-7656","1699-3993","1699-4019"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4360969288","host_organization_name":"Prous Science","host_organization_lineage":["https://openalex.org/P4360969288"],"host_organization_lineage_names":["Prous Science"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs of Today","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005732386","display_name":"Sarah A. Holstein","orcid":"https://orcid.org/0000-0002-9342-5635","observed_orcids":["https://orcid.org/0000-0002-9342-5635"]},"institutions":[{"id":"https://openalex.org/I59130452","display_name":"University of Nebraska Medical Center","ror":"https://ror.org/00thqtb16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I59130452"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sarah A. Holstein","raw_affiliation_strings":["Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. sarah.holstein@unmc.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. sarah.holstein@unmc.edu","institution_ids":["https://openalex.org/I59130452"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5005732386"],"corresponding_institution_ids":["https://openalex.org/I59130452"],"apc_list":null,"apc_paid":null,"fwci":0.6071,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.64161763,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"59","issue":"1","first_page":"1","last_page":"16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.649399995803833,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.649399995803833,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.3458999991416931,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ciltacabtagene-autoleucel","display_name":"ciltacabtagene autoleucel","score":0.9919999837875366},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.859000027179718},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.8109999895095825},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.9350000023841858},{"id":"https://openalex.org/keywords/heavily-pretreated-patients","display_name":"heavily pretreated patients","score":0.7689999938011169},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8100000023841858},{"id":"https://openalex.org/keywords/real-world-utilization","display_name":"real-world utilization","score":0.9139999747276306},{"id":"https://openalex.org/keywords/clinical-trial-data","display_name":"clinical trial data","score":0.6729999780654907}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9512484073638916},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.802700400352478},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.7453145384788513},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6681591272354126},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6013704538345337},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5474187135696411},{"id":"https://openalex.org/C3017976582","wikidata":"https://www.wikidata.org/wiki/Q179661","display_name":"First line treatment","level":3,"score":0.45638707280158997},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.420486181974411},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.41248995065689087},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39281779527664185},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3349330723285675},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3153666853904724},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.21652525663375854},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.15842047333717346},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000076962","descriptor_name":"Receptors, Chimeric Antigen","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016219","descriptor_name":"Immunotherapy, Adoptive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053301","descriptor_name":"B-Cell Maturation Antigen","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1358/dot.2023.59.1.3509751","doi":"https://doi.org/10.1358/dot.2023.59.1.3509751","is_oa":false,"landing_page_url":"https://doi.org/10.1358/dot.2023.59.1.3509751","pdf_url":null,"source":{"id":"https://openalex.org/S202615048","display_name":"Drugs of today","issn_l":"0025-7656","issn":["0025-7656","1699-3993","1699-4019"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4360969288","host_organization_name":"Prous Science","host_organization_lineage":["https://openalex.org/P4360969288"],"host_organization_lineage_names":["Prous Science"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs of Today","raw_type":"journal-article"},{"id":"pmid:36811414","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36811414","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs of today (Barcelona, Spain : 1998)","raw_type":"Review"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4294219068","https://openalex.org/W4391920012","https://openalex.org/W4205492958","https://openalex.org/W4303473066","https://openalex.org/W3210549609","https://openalex.org/W3170578809","https://openalex.org/W4310159091","https://openalex.org/W3130235402","https://openalex.org/W4387034098","https://openalex.org/W4396864101"],"abstract_inverted_index":{"While":[0],"treatment":[1],"options":[2],"for":[3,95],"multiple":[4,18],"myeloma":[5],"(MM)":[6],"are":[7,110],"continuing":[8],"to":[9,47,55,112,114],"expand,":[10],"this":[11,48,86],"disease":[12],"remains":[13],"one":[14],"characterized":[15],"by":[16,66],"requiring":[17],"lines":[19],"of":[20,26,32,57,120,134],"therapy,":[21],"with":[22],"generally":[23],"decreasing":[24],"effectiveness":[25],"each":[27],"subsequent":[28],"line.":[29],"The":[30],"development":[31],"B-cell":[33],"maturation":[34],"antigen":[35,38],"(BCMA)-directed":[36],"chimeric":[37],"receptor":[39],"(CAR)":[40],"T-cell":[41,61],"therapy":[42,62],"has":[43],"proven":[44],"an":[45],"exception":[46],"rule.":[49],"In":[50,85,122],"the":[51,58,67,90,118,126,131],"trial":[52,93],"that":[53,109,128],"led":[54],"approval":[56],"BCMA":[59],"CAR":[60],"ciltacabtagene":[63],"autoleucel":[64],"(cilta-cel)":[65],"U.S.":[68],"Food":[69],"and":[70,75],"Drug":[71],"Administration":[72],"(FDA),":[73],"deep":[74],"durable":[76],"response":[77],"rates":[78],"were":[79],"observed":[80],"in":[81,117],"heavily":[82],"pretreated":[83],"patients.":[84],"review":[87],"we":[88,124],"summarize":[89],"available":[91],"clinical":[92],"data":[94],"cilta-cel,":[96],"including":[97],"discussion":[98],"on":[99],"notable":[100],"adverse":[101],"events,":[102],"as":[103,105],"well":[104],"discuss":[106,125],"ongoing":[107],"studies":[108],"likely":[111],"lead":[113],"paradigm":[115],"changes":[116],"management":[119],"MM.":[121],"addition,":[123],"issues":[127],"currently":[129],"surround":[130],"real-world":[132],"utilization":[133],"cilta-cel.":[135]},"counts_by_year":[{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-01-24T00:00:00"}